Reduction in tumor burden has been previously demonstrated in a PCa xenograft model treated with concurrent HDAC/mTOR inhibition [19] and more recently in renal cell carcinoma (RCC) xenograft models [37]. The gene discussed is HDAC9; the disease is neoplasm.